RxDoctor Payments Data

Cherika O'Brien

Family · Richmond, INNPI 1174284558

Payments from drug & device makers

$1,862in general payments, 2019–2025

Across 122 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$539
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$181
  • Vanda Pharmaceuticals Inc.$165
  • Novo Nordisk$132
  • GSK$130
  • Otsuka America Pharmaceutical, Inc.$112
  • plus $603 from 15 others

What the payments were for

  • Food & beverage$1,862100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,862 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$7,635
Medicare patients
103
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin18$12,509
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,320
RybelsusSemaglutide12$11,889
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,667
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl43$2,237
Albuterol Sulfate HfaAlbuterol Sulfate46$1,489
Omeprazole44$462
Hydroxyzine Hcl14$386
Atorvastatin Calcium74$380
Amlodipine Besylate47$304
Gabapentin33$261
Ondansetron Hcl14$224
Metoprolol Succinate13$207
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$199
Famotidine17$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$130$17,98631 claims
Novo NordiskRybelsus$132$11,88912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Richmond

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →